<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0484-7903</journal-id>
<journal-title><![CDATA[Revista mexicana de anestesiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. anestesiol.]]></abbrev-journal-title>
<issn>0484-7903</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Anestesiología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0484-79032024000300158</article-id>
<article-id pub-id-type="doi">10.35366/116167</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia y seguridad de la reversión de la relajación neuromuscular con sugammadex vs neostigmina inducida por vecuronio]]></article-title>
<article-title xml:lang="en"><![CDATA[Efficacy and safety of reversal of neuromuscular relaxation with sugammadex vs vecuronium-induced neostigmine]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Atonal-Tenorio]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mancilla-Hernández]]></surname>
<given-names><![CDATA[Eleazar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera-Federico]]></surname>
<given-names><![CDATA[Luz María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Investigación en el Área de la Salud A.C  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Socia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<volume>47</volume>
<numero>3</numero>
<fpage>158</fpage>
<lpage>163</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0484-79032024000300158&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0484-79032024000300158&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0484-79032024000300158&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la neostigmina y el sugammadex son alternativas para reversión de la relajación neuromuscular inducida por vecuronio.  Material y métodos:  ensayo clínico, aleatorizado, en paciente con relajación neuromuscular inducida por vecuronio a 0.1 mg/kg de peso ideal; para realizar la reversión de la relajación neuromuscular (RRNM), se dividieron en dos grupos: grupo A sugammadex de 2 mg/kg; y grupo B neostigmina 0.04 mg/kg más 0.02 mg/kg (ambos con peso ideal). Se comparó el tiempo de RRNM, la presencia de eventos adversos y la aparición de la relajación residual en el área de cuidados postanestésicos. El análisis estadístico se realizó con U de Mann-Whitney, &#967;2 y se calculó el tamaño del efecto con g de Hedges.  Resultados:  se incluyeron 76 pacientes en dos grupos: sugammadex y neostigmina, el grupo A presentó una RRNM a los cuatro minutos y el grupo B a los 12 minutos con una p &lt; 0.01 con una correlación r = 0.08, además grupo A presentó eventos adversos en 2.63% y grupo B 89.46% con una p &lt; 0.001.  Conclusiones:  el sugammadex presentó un menor tiempo para la RRNM inducida por vecuronio y menores eventos adversos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  neostigmine and sugammadex are alternatives for reversal of vecuronium-induced neuromuscular relaxation.  Material and methods:  clinical trial, randomized in patients with neuromuscular relaxation induced by vecuronium at 0.1 mg/kg of ideal weight; to perform the reversion of neuromuscular relaxation (RRNM), they were divided into two groups: group A sugammadex of 2 mg/kg and group B neostigmine .04 mg/kg plus .02 mg/kg (both ideal weight). RRNM time, presence of adverse events and occurrence of residual relaxation in the post-anesthesia care area were compared. Statistical analysis was performed with Mann-Whitney U, &#967;2 and the effect size was calculated with g Hedges.  Results:  76 patients were included in two groups: sugammadex and neostigmine, group A presented RRNM at four minutes and group B at 12 minutes with a p &lt; 0.01 with a correlation r = 0.08, also group A presented adverse events in 2.63% and group B 89.46% with a p &lt; 0.001.  Conclusions:  sugammadex presented shorter time to vecuronium-induced NRRMR and lower adverse events.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[sugammadex]]></kwd>
<kwd lng="es"><![CDATA[neostigmina]]></kwd>
<kwd lng="es"><![CDATA[vecuronio]]></kwd>
<kwd lng="en"><![CDATA[sugammadex]]></kwd>
<kwd lng="en"><![CDATA[neostigmine]]></kwd>
<kwd lng="en"><![CDATA[vecuronium]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lien]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[Relajantes Musculares en Anestesia y Farmacología de los relajantes musculares y sus antagonistas: Miller RD. Miller anestesia]]></source>
<year>2012</year>
<edition>8va</edition>
<page-range>625-79</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aldrete]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Guevara-López]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Capmourteres]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<source><![CDATA[Texto de anestesiología teórico-práctica]]></source>
<year>2004</year>
<edition>2da</edition>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[El Manual Moderno]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[EI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacción farmacológica de los bloqueadores neuromusculares con fármacos de uso anestesiológico]]></article-title>
<source><![CDATA[Rev Cuba Anestesiol Reanim]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[MCA]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[RJJ]]></given-names>
</name>
<name>
<surname><![CDATA[Linares]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacoeconomía de sugammadex para la reversión de la relajación neuromuscular con anestesia general en el Hospital Ángeles Pedregal]]></article-title>
<source><![CDATA[Acta Med]]></source>
<year>2018</year>
<volume>16</volume>
<page-range>209-18</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mille-Loera]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[González-Chon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugammadex: mitos y realidades]]></article-title>
<source><![CDATA[Rev Mex Anest]]></source>
<year>2016</year>
<volume>39</volume>
<page-range>82-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Acción del sugammadex y de los bloqueantes neuromusculares: rocuronio y vecuronio en neuronas en cultivo primario]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Valencia ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Valencia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bustamante]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugammadex: ¿Un verdadero aporte en la reversión del bloqueo neuromuscular?]]></article-title>
<source><![CDATA[Rev Chil Anest]]></source>
<year>2011</year>
<volume>40</volume>
<page-range>52-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Valancia]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relajación residual en la unidad de cuidados posanestésicos]]></article-title>
<source><![CDATA[Repert med cir]]></source>
<year>2015</year>
<volume>24</volume>
<page-range>254-60</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<source><![CDATA[&#8220;Incidencia de parálisis muscular residual vecuronio versus rocuronio en la Unidad de Cuidados Postanestesicos del Hospital Cruz Roja Mexicana&#8221;]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Toluca ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Autónoma del estado de México]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva e Goncalves]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Vasconcelos Viera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro da Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Santiago Gomez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Residual neuromuscular blockade and late neuromuscular blockade at the post-anesthetic recovery unit: prospective cohort study]]></article-title>
<source><![CDATA[Brazilian Journal of Anesthesiology (English Edition)]]></source>
<year>2021</year>
<volume>71</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-43</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Silverio]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra-Villalba]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Elizalde-Flores]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vélez-Méndez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rnedón-Macías]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia y seguridad del uso de sugammadex contra neostigmina en la reversión del bloqueo neuromuscular]]></article-title>
<source><![CDATA[Rev Sanid Milit Mex]]></source>
<year>2015</year>
<volume>69</volume>
<page-range>18-24</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[JTJ]]></given-names>
</name>
<name>
<surname><![CDATA[Athíe]]></surname>
<given-names><![CDATA[GJM]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reversión satisfactoria y eficaz del bloqueo neuromuscular residual. Neostigmina versus sugammadex en pacientes sometidos a rinoseptoplastia en el Hospital Ángeles Mocel]]></article-title>
<source><![CDATA[Acta Med]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>189-93</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kizilay]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saracoglu]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Eti]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gogus]]></surname>
<given-names><![CDATA[FY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery]]></article-title>
<source><![CDATA[J Clin Anesth]]></source>
<year>2016</year>
<volume>28</volume>
<page-range>30-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordero-Escobar]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Martínez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reversión o no del bloqueo neuromuscular posanestésico]]></article-title>
<source><![CDATA[Rev cuba anestesiol reanim]]></source>
<year>2016</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Torre-Anderson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre-Buendía]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zamora-García]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia y seguridad del sugammadex]]></article-title>
<source><![CDATA[Rev Mex Anest]]></source>
<year>2014</year>
<volume>37</volume>
<page-range>77-82</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estrada-Cortinas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes-Puga]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Camarena-Ruiz]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cambios hemodinámicos por sugammadex en el paciente cardiópata. Anest]]></article-title>
<source><![CDATA[Méx]]></source>
<year>2016</year>
<volume>28</volume>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barajas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Camarena]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castilleros]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Castorena]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Anda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinación de la incidencia de la parálisis residual postanestésica con el uso de agentes bloqueadores neuromusculares en México]]></article-title>
<source><![CDATA[Rev Mex Anest]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>181-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khuenl-Brady]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Wattwil]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vanacker]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Lora-Tamayo]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Rietbergen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Gómez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>2010</year>
<volume>110</volume>
<page-range>64-73</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abreu-Darias]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero-Escobar]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Martinez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reversión del bloqueo neuromuscular inducido por vecuronio: sugammadex o neostigmina]]></article-title>
<source><![CDATA[Rev cuba anestesiol reanim]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>253-67</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Kopman]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neostigmine as an antagonist of residual block: best practices do not guarantee predictable results]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2018</year>
<volume>121</volume>
<page-range>335-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallejo-Tello]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<source><![CDATA[Reversión del bloqueo neuromuscular inducido por vecuronio y rocuronio usando neostigmina]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Trujillo, Perú ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Trujillo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hristovska]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Duch]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Allingstrup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Afshari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults]]></source>
<year>2017</year>
<publisher-name><![CDATA[Cochrane Libr]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
